Dry powder inhalant for anesthesia and preparing method thereof

A dry powder inhaler and powder technology, applied in the field of anesthetized dry powder inhaler and its preparation, can solve the problems of increased medication risk, large dose, poor stability, etc., and achieve simple and easy preparation process, good content uniformity, powder good fluidity

Inactive Publication Date: 2017-12-01
CHONGQING YUBEIHAI TECH CO LTD
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The efficacy and use of these sedatives have the following problems: (1) chloral hydrate oral agent: it is the most commonly used sedative agent for children before examination in outpatient clinics. Because its mouthfeel is very bitter, many children refuse to take it or cause vomiting after taking it. Increased risk of aspiration, even life-threatening
In addition, the metabolites of chloral hydrate are active and sometimes cause delayed awakening; at the same time, the first-pass effect of the drug is obvious, and the sedative effect is uncertain, which often leads to sedation failure, and many children often need repeated medications
(2) Oral midazolam: the sedative effect is not good, and the success rate is only 60-75%
(3) Lumin sodium intramuscular injection: the success rate of sedation is about 80%, but it is accompanied by painful stimulation, which will cause harm to children
[0003] Dexmedetomidine hydrochloride is the dextro isomer of medetomidine, which is a derivative of imidazoles. It is a highly selective α2 receptor agonist, and its chemical name is: (+)-4-(S) -[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole hydrochloride acts on α2 receptors in the nucleus of the locus coeru

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dry powder inhalant for anesthesia and preparing method thereof
  • Dry powder inhalant for anesthesia and preparing method thereof
  • Dry powder inhalant for anesthesia and preparing method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] A dry powder inhaler for anesthesia, prepared according to the following steps:

[0025] Element

Dosage (parts by weight)

Dexmedetomidine Hydrochloride

1 copy

Ketamine hydrochloride

800 copies

lactose

2250 copies

Mannitol

1450 copies

β-cyclodextrin

2350 copies

Magnesium stearate

1900 copies

Sodium carbonate

110 copies

[0026] Preparation process:

[0027] 1. Pretreatment of raw and auxiliary materials: mix the dexmedetomidine hydrochloride, ketamine hydrochloride, and β-cyclodextrin in the prescribed amount after sterilization, and then put them in an airflow ultrafine pulverizer, and pulverize them into particles with a particle size of less than 5 μm. powder, obtain powder 1, and set aside; take another sterilized prescription amount of lactose, mannitol, and sodium carbonate, mix them, place them in an airflow ultrafine pulverizer, and pulverize them into powders with a ...

Embodiment 2

[0066] A dry powder inhaler for anesthesia, prepared according to the following steps:

[0067] Element

Dosage (parts by weight)

Dexmedetomidine Hydrochloride

1 copy

Ketamine hydrochloride

700 copies

lactose

2200 copies

Mannitol

1300 copies

β-cyclodextrin

2200 copies

Magnesium stearate

1800 copies

Sodium carbonate

100 copies

[0068] Preparation process: prepared according to the preparation process of Example 1.

[0069] According to the test method of embodiment 1, the sample stability test result of embodiment 2 shows that the sample quality is stable in accelerating June, and the quality is stable in 36 months for a long time, so the validity period of this product is at least 36 months; The angle is less than 39°, which shows that the powder of Example 2 has good fluidity; the content uniformity measurement test result shows that the RSD of this product is less than 1%, which...

Embodiment 3

[0071] A dry powder inhaler for anesthesia, prepared according to the following steps:

[0072] Element

Dosage (parts by weight)

Dexmedetomidine Hydrochloride

1 copy

Ketamine hydrochloride

900 copies

lactose

2300 copies

Mannitol

1500 copies

β-cyclodextrin

2500 copies

Magnesium stearate

2000 copies

Sodium carbonate

120 copies

[0073] Preparation process: prepared according to the preparation process of Example 1.

[0074] By the test method of embodiment 1, the sample stability test result of embodiment 3 shows that the sample quality is stable in accelerating June, and the quality is stable in 36 months for a long time, so this product is valid for at least 36 months; The angle is less than 39°, which shows that the powder of Example 3 has good fluidity; the content uniformity measurement test result shows that the RSD of this product is less than 1%, which shows that this produc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to view more

Abstract

Disclosed is a dry powder inhalant for anesthesia. The dry powder inhalant for the anesthesia is prepared by the following steps that dexmedetomidine hydrochloride injection and ketamine hydrochloride are used as raw materials, a certain amount of carriers, active protective agents, lubricating agents and pH adjusting agents are added, and pretreatment, mixing, drying, total mixing and injected packing are conducted. According to the dry powder inhalant for the anesthesia, special medicine feeding channels do not need to be established, in the medicine taking process, patients are painless, the compliance is good, the stability in the product storing process is good, pH changing and impurity increment in the storing process are low, the impurity increment within the expiry date is only 0.06%, the expiry date of products reaches above 36 months, the flowability of the powder is good, the angle of repose is less than 42 degrees, the content uniformity is good, the content RSD of a plurality of points is less than 1%, the preparing process is simple and easy to operate, and the dry powder inhalant for the anesthesia is worthy of market promotion.

Description

technical field [0001] The invention mainly relates to the technical field of pharmacy, in particular to a dry powder inhaler for anesthesia and a preparation method thereof. Background technique [0002] At present, the commonly used sedative drugs before examination in China are oral chloral hydrate or midazolam, and intramuscular injection of sodium lumina. The efficacy and use of these sedatives have the following problems: (1) chloral hydrate oral agent: it is the most commonly used sedative agent for children before examination in outpatient clinics. Because its mouthfeel is very bitter, many children refuse to take it or cause vomiting after taking it. Increased risk of aspiration, even life threatening. In addition, the metabolites of chloral hydrate are active and sometimes cause delayed awakening; at the same time, the drug has an obvious first-pass effect, and the sedative effect is uncertain, which often leads to sedation failure, and many children often need re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/72A61K9/14A61K47/40A61K47/26A61K47/12A61K47/02A61K31/4174A61K31/137A61P23/00
CPCA61K9/0073A61K9/143A61K9/145A61K9/146A61K31/137A61K31/4174A61K2300/00
Inventor 徐颖叶茂
Owner CHONGQING YUBEIHAI TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products